342 related articles for article (PubMed ID: 29860707)
1. Using a cancer registry to capture signals of adverse events following immune and targeted therapy for melanoma.
Aguiar JP; Cardoso Borges F; Murteira R; Ramos C; Gouveia E; Passos MJ; Miranda A; da Costa FA
Int J Clin Pharm; 2018 Aug; 40(4):852-861. PubMed ID: 29860707
[TBL] [Abstract][Full Text] [Related]
2. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK
Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553
[TBL] [Abstract][Full Text] [Related]
3. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
4. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.
McQuade JL; Daniel CR; Hess KR; Mak C; Wang DY; Rai RR; Park JJ; Haydu LE; Spencer C; Wongchenko M; Lane S; Lee DY; Kaper M; McKean M; Beckermann KE; Rubinstein SM; Rooney I; Musib L; Budha N; Hsu J; Nowicki TS; Avila A; Haas T; Puligandla M; Lee S; Fang S; Wargo JA; Gershenwald JE; Lee JE; Hwu P; Chapman PB; Sosman JA; Schadendorf D; Grob JJ; Flaherty KT; Walker D; Yan Y; McKenna E; Legos JJ; Carlino MS; Ribas A; Kirkwood JM; Long GV; Johnson DB; Menzies AM; Davies MA
Lancet Oncol; 2018 Mar; 19(3):310-322. PubMed ID: 29449192
[TBL] [Abstract][Full Text] [Related]
5. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study.
Gullo G; Rubatto M; Fava P; Brizio M; Tonella L; Ribero S; Medri M; Avallone G; Mastorino L; Fierro MT; Stanganelli I; Quaglino P
Dermatol Ther; 2022 Jun; 35(6):e15492. PubMed ID: 35384181
[TBL] [Abstract][Full Text] [Related]
8. A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients.
Cortellini A; Buti S; Agostinelli V; Bersanelli M
Semin Oncol; 2019; 46(4-5):362-371. PubMed ID: 31727344
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma.
Robert C; Hwu WJ; Hamid O; Ribas A; Weber JS; Daud AI; Hodi FS; Wolchok JD; Mitchell TC; Hersey P; Dronca R; Joseph RW; Boutros C; Min L; Long GV; Schachter J; Puzanov I; Dummer R; Lin J; Ibrahim N; Diede SJ; Carlino MS; Joshua AM
Eur J Cancer; 2021 Feb; 144():182-191. PubMed ID: 33360855
[TBL] [Abstract][Full Text] [Related]
10. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Wang DY; Salem JE; Cohen JV; Chandra S; Menzer C; Ye F; Zhao S; Das S; Beckermann KE; Ha L; Rathmell WK; Ancell KK; Balko JM; Bowman C; Davis EJ; Chism DD; Horn L; Long GV; Carlino MS; Lebrun-Vignes B; Eroglu Z; Hassel JC; Menzies AM; Sosman JA; Sullivan RJ; Moslehi JJ; Johnson DB
JAMA Oncol; 2018 Dec; 4(12):1721-1728. PubMed ID: 30242316
[TBL] [Abstract][Full Text] [Related]
11. i-Move, a personalised exercise intervention for patients with advanced melanoma receiving immunotherapy: a randomised feasibility trial protocol.
Hyatt A; Gough K; Murnane A; Au-Yeung G; Dawson T; Pearson E; Dhillon H; Sandhu S; Williams N; Paton E; Billett A; Traill A; Andersen H; Beedle V; Milne D
BMJ Open; 2020 Feb; 10(2):e036059. PubMed ID: 32114479
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance.
Fornasier G; Taborelli M; Francescon S; Polesel J; Aliberti M; De Paoli P; Baldo P
Int J Clin Pharm; 2018 Aug; 40(4):795-802. PubMed ID: 29785683
[TBL] [Abstract][Full Text] [Related]
14. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors.
Moreira A; Loquai C; Pföhler C; Kähler KC; Knauss S; Heppt MV; Gutzmer R; Dimitriou F; Meier F; Mitzel-Rink H; Schuler G; Terheyden P; Thoms KM; Türk M; Dummer R; Zimmer L; Schröder R; Heinzerling L
Eur J Cancer; 2019 Jan; 106():12-23. PubMed ID: 30453170
[TBL] [Abstract][Full Text] [Related]
15. Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma.
Basile D; Lisanti C; Pizzichetta MA; Baldo P; Fornasier G; Lo Re F; Corona G; Puglisi F
Recent Pat Anticancer Drug Discov; 2019; 14(3):203-225. PubMed ID: 31362664
[TBL] [Abstract][Full Text] [Related]
16. Cytokine release syndrome as an important differential diagnosis of severe skin toxicity with organ damage during switch from immunotherapy to targeted therapy in metastatic melanoma.
Dimitriou F; Mangana J; Micaletto S; Braun RP; Dummer R
Melanoma Res; 2019 Feb; 29(1):107-108. PubMed ID: 30557221
[No Abstract] [Full Text] [Related]
17. [Acceptability and effectiveness of immunotherapy in patients with melanoma].
Valnet-Rabier MB; Marcucci C; Limat S; Davani S; Aubin F; Nerich V
Therapie; 2019 Jun; 74(3):355-367. PubMed ID: 30193804
[TBL] [Abstract][Full Text] [Related]
18. Hair Depigmentation and Hair Loss in Advanced Melanoma Treated with Combined Immunotherapy and Targeted Therapy.
Dimitriou F; Mangana J; Dummer R
Acta Derm Venereol; 2020 Jan; 100(1):adv00007. PubMed ID: 31626322
[No Abstract] [Full Text] [Related]
19. Incidence of Placebo Adverse Events in Randomized Clinical Trials of Targeted and Immunotherapy Cancer Drugs in the Adjuvant Setting: A Systematic Review and Meta-analysis.
Chacón MR; Enrico DH; Burton J; Waisberg FD; Videla VM
JAMA Netw Open; 2018 Dec; 1(8):e185617. PubMed ID: 30646278
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
Hwang SJ; Carlos G; Wakade D; Byth K; Kong BY; Chou S; Carlino MS; Kefford R; Fernandez-Penas P
J Am Acad Dermatol; 2016 Mar; 74(3):455-61.e1. PubMed ID: 26793994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
